Stocks Health care XLO
NASDAQ · Health careXilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc. brought in $64.1M of revenue over the twelve months to June 30, 2026. It posted a net loss of $21.8M. In fiscal 2025 capital spending exceeded operating cash flow by $5.5M. At June 30, 2026 it held $136M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
What Xilio Therapeutics, Inc. does
Xilio Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker XLO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $43.8M | -$35M | -$4.19 | -$5.5M |
| 2024 | $6.3M | -$58.2M | -$15.24 | -$18.4M |
| 2023 | n/a | -$76.4M | -$38.87 | -$69.1M |
| 2022 | n/a | -$88.2M | -$45.02 | -$77.6M |
| 2021 | n/a | -$75.8M | -$189.03 | -$81.9M |
| 2021 | n/a | -$55.2M | -$1,473.95 | -$38.3M |
Latest SEC filings
What Xilio Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026
- August 12, 2026
- June 12, 2026
- May 27, 2026
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
Questions about XLO
What does Xilio Therapeutics, Inc. do?
Xilio Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker XLO.
Is Xilio Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $21.8M on revenue of $64.1M.
How much revenue does Xilio Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Xilio Therapeutics, Inc. reported revenue of $64.1M.
When did Xilio Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from August 14, 2026.
Similar companies
Follow XLO
Get an email when Xilio Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow XLO: get an email when it filesWhere the numbers come from
Financial figures are the values Xilio Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.